Pharmacological activities of heparin chains: Should our past knowledge be revised??

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 2-9

  Agnelli, Giancarlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Antithrombin III; Glycosaminoglycans; Heparin; Low molecular weight heparins; Thrombin

Indexed keywords

ANTITHROMBIN III; ENOXAPARIN; GLYCOSAMINOGLYCAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN;

BLOOD CLOTTING; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; ENOXAPARIN; FACTOR XA; FEMALE; HALF-LIFE; HEPARIN; HUMANS; MALE; PROTHROMBIN;

EID: 0029996141     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217266     Document Type: Article

References (33)

1. Johnson EA. Mulloy B: The molecular-weight range of commercial heparin preparations. Carbohydr Res 1979;51:119-126.
2. Abildgaard U: Highly purified antithrombin 111 with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 1968; 21:89-96.
3. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B. Gatti G: Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin 111 and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983;116:492-499.
4. Rosenberg RD. Lam L: Correlation between structure and function of heparin. Proc Natl Acad Sci USA 1979;76:1218-1225.
5. Lindahl U, Thunberg L, Backstrom G: Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chcm 1984;259:12368-12375.
6. Nesheim ME: A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin. J Biol Chem 1983;258:14708-14716.
7. Hemker HC, Bcguin S: A rational approach to heparins. Nouv Rev Fr Hematol 1992;34:5-6.
8. Caranobe C, Petitou M, Dupouy D, Gabaig AM, Sic P, Buchnan MR, Boneu B: Heparin fraction with high and low affinities to anti-thrombin III are cleared at different rates. Thromb Res 1986;43:635-641.
9. Barzu T, Van Rijn JLML, Petitou M, Mohlo P, Tobelem G, Caen J: Endothelial binding sites for heparin. Biochem J 1986:238:847-854.
10. Hirsh J, Ofosu FA, Levine M: The development of low molecular weight heparins for clinical use; in Verstraete M, Vermylen J, Lijnen HR. Arnout J (cds): Thrombosis and Haemostasis 1987. Leuven, Leuven University Press, 1987.
11. Buchanan MR, Boneu B. Ofosu F, Hirsh J: The relative importance of thrombin inhibition and factor Xa inhibition to antithrombotic effects of heparin. Blood 1985:65:198-205.
12. Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan M. Hirsh J: The importance of thrombin inhibition for the expression of the anticoagulant activity of heparin, dermatan sulphate, low molecular weight heparin and pentosan poly-sulphate. Br J Haematol 1985:60: 694-699.
13. Bendetowicz AV, Beguin S. Caplain H, Hemker HC: Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxa-parin) after subcutaneous injection, comparison with unfractionated heparin-A three way cross study in human volunteers. Thromb Hae-most 1994;71:305-312.
14. Bara L, Bloch MF, Zitoun D, Sama-ma M. Collignon F, Frydman A, Uzan A, Bouthier J: Comparative effects of cnoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993:69: 443-452.
15. Agnelli G, lorio A, Renga C. Bos-chetti E, Nenci GG, Ofosu FA, Hirsh J: Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995:92:2819-2824.
16. Bratt G, Tomebohn E, Granqvist S, Aberg W, Lockner D: A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985;54:813-820.
17. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gott-schalk P, Hoeg V, Aandahl M, Haugen K, Locrurn F, Scheel B: Subcutaneous heparin treatment of deep vein thrombosis: A comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16:30-38.
18. Faivre R. Ncuhart E, Kieffcr Y, Toulemondc F, Bassand JP, Mavrat JP: Subcutaneous administration of a low molecular weight heparin CY222 compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thromb Haemost 1987:58:430-437.
19. Bratt G, Aberg W, Johansson M, Torncbohm E. Granqvist S, Lock-ner D: Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thromb Haemost 1990:64:506-511.
20. Collaborative European Multicentre Study: A randomized trial of subcutaneous low' molecular weight heparin (CY216) compared with intravenous unfractionatcd heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991;65:251-256.
21. Lopaciuk S, Meissner J. Filipecki S, Zawilska K, Sowier J. Ciesielski L, Bielawiec M. Glowinski S, Czcsto-chowska E: Subcutaneous low molecular weight heparin versus subcutaneous unfractionatcd heparin in the treatment of deep vein thrombosis: A Polish multicenter trial. Thromb Haemost 1992;68:14-21.
22. Simonneau G, Charbonnier B, De-cosus H. Planchon B, Ninet J, Sie P. Silsigucn M. Combe S: Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment of proximal deep venous thrombosis: A multicenter randomized trial. DVTENOX study. Arch Intern Med 1993; 153: 1542-1549.
23. Prandoni P. Lensing AWA, Biiller HR, Carta M, Cogo A, Vigo M, Ca-sara D, Ruol A, ten Cate JW: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339:441-450.
24. Hull RD, Raskob GE, Pineo GF. Green D, Trowbridge AA, Elliott GG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J. Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R: Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-981.
25. Leizorovicz A, Simonneau G, De-cousus H: Comparison of low molecular weight heparin and unfractionated heparin in the treatment of dVT: A mcta-analysis. Thromb Haemost 1993:69:647-652.
26. Lensing AWA, Prins MH, Davidson BL, Hirsh J: Treatment of deep vein thrombosis with low-molecular-weight heparin: A meta-analysis. Arch Intern Med 1995; 155:601-607.
27. Agnelli G, Mclelli P, Renga C, Leone M, Alatri A, Parise P. Nenci GG: Plasma thrombin neutralization assay (PTNA): A sensitive method to detect heparin in plasma. Thromb Res 1992; 65:S 132.
28. Gibaldi M, Perrier D: Pharmacokinetics, cd 2. New York, Dekker, 1982.
29. SAS Institute: SAS User’s Guide: Statistics, ed 4. Cary. SAS Institute, version 6, 1990.
30. Landaw EM, Di Stefano J: Multiexponential. multicompartmcntal, and non-compartmental modelling. II: Data analysis and statistical considerations. Am J Physiol 1985:246: 665-671.
31. Bara L, Billaud E, Gramond G, Kher A, Samama M: Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985;39:631-637.
32. Harenberg J, Wiirzer B. Zimmer-mann R. Schlcttler G: Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res 1986:44:549-556.
33. Frydman A, Bara L, Leroux Y, Wo-ler M. Chauliac F, Duchier J, Samama M: The antithrombotic activity and pharmacokinetics of enoxapar-in, a low molecular weight heparin, in man given single subcutaneous doses of 20 up to 80 mg. J Clin Pharmacol 1988;28:609-618.